SanjeevPathakMD

Psychiatry • Wilmington, DE

Child & Adolescent Psychiatry

Psychiatrist

Join to view full profile

Dr. Pathak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pathak's full profile

Already have an account?

Office
825 Washington St
Wilmington, DE 19801
Phone+1 302-655-7110

Fax+1 302-655-6185

Education & Training

Cincinnati Children's Hospital Medical CenterFellowship, Child and Adolescent Psychiatry, 1999 - 2001
University of Cincinnati Medical Center/College of MedicineResidency, Psychiatry, 1996 - 1999
All India Institute of Medical SciencesClass of 1992

Certifications & Licensure

OH State Medical License 1999 - 2026
DE State Medical License 2010 - 2015

Clinical Trials

A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD) Start of enrollment: 2014 Feb 01
Completed
Phase 3
A Long-Term Safety Study of ALKS 5461 Start of enrollment: 2014 May 01
Completed
Phase 3
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study Start of enrollment: 2014 May 01
Completed
Phase 3
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study Start of enrollment: 2014 May 01
Completed
Phase 3
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder Start of enrollment: 2014 May 01
Completed
Phase 2
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study Start of enrollment: 2014 Jul 01
Completed
Phase 3
A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users Start of enrollment: 2014 Aug 01
Completed
Phase 1
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia Start of enrollment: 2017 Nov 15
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

43 citations
Efficacy and Safety of Quetiapine in Adolescents with Schizophrenia Investigated in a 6-Week, Double-Blind, Placebo-Controlled Trial
Robert L. Findling, Kathleen M. McKenna, Willie Earley, Jill Stankowski, Sanjeev Pathak
Journal of Child and Adolescent Psychopharmacology. 2012-10-19
181 citations
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects
Gerard Sanacora, Mark A. Smith, Sanjeev Pathak, Su Hl, Boeijinga Ph
Molecular Psychiatry. 2014-09-01
84 citations
Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.
Gerard Sanacora, Michael R Johnson, Arif Khan, Sarah Atkinson, Robert R Riesenberg
Neuropsychopharmacology. 2017-03-01

Authored Content

S99. Evaluation of Abuse Potential of Samidorphan in Healthy, Nondependent, Recreational Opioid UsersApril 2018
S99. Evaluation of Abuse Potential of Samidorphan in Healthy, Nondependent, Recreational Opioid UsersApril 2018